InvestSMART

Bio-Gene Technology Ltd (ASX:BGT)

ALERT: Price-sensitive ASX Announcement for BGT
Current share price for BGT : $0.016 -0.002 (-11.11%)+
Announcement
Release
31 Jul 2026 11:25AM
Price at Release
$0.018
Full Release
download
Summary
Bio-Gene Technology Limited, an Australian agtech company, reported its quarterly activities for the period ending 30 June 2026. The company highlighted the expansion of its Flavocide® and Qcide® mosquito vector control evaluation into Asia, targeting mosquito species responsible for diseases like dengue, chikungunya, and Zika. Testing is expected to be completed by Q4 2026. Bio-Gene is also working towards launching Qcide in Japan in collaboration with Sumitomo Corporation. The company secured $3.275 million through capital raising activities to support its programs and reported a cash balance of $1.94 million. Additionally, a US patent was allowed for Flavocide combinations, expanding Bio-Gene's intellectual property portfolio. Peter May of Bio-Gene received the Envu Excellence Award for his contributions to pest management.
Key Points
  • Bio-Gene expanded mosquito vector control evaluation into Asia.
  • Testing in Singapore aligned with WHO guidelines, targeting completion by Q4 2026.
  • Bio-Gene aims to launch Qcide in Japan with Sumitomo Corporation.
  • Raised $3.275 million to support Flavocide® and Qcide® programs.
  • Reported cash balance of $1.94 million as of June 30, 2026.
  • US patent allowed for Flavocide combinations, enhancing IP portfolio.
  • Peter May received Envu Excellence Award for pest management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.